NCT00801814CompletedPhase 2
Effect of Adding Escalating Doses of a Novel Highly Viscous Polysaccharide to Either a Liquid or a Solid Test Meal on Post Prandial Glycemia in Healthy Subjects: Determination of the Glycemic Reduction Index Potential (GRIP)
Glycemic Index Laboratories, Inc2 sites in 1 country20 target enrollmentStarted: April 2006Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- postprandial glycemia
Study Overview
Brief Summary
To determine palatability and extent to which escalating doses of a novel highly viscous polysaccharide [NVP] reduces postprandial glycemia when added to a liquid and a solid meal.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •healthy individuals
- •18-75 years old
- •BMI less than 35 kg/m2
Exclusion Criteria
- •Medications influencing gastrointestinal function
- •Pregnancy
Outcomes
Primary Outcomes
postprandial glycemia
Time Frame: Acute study measuring postprandial glucose levels over 2 hours
Secondary Outcomes
- The glucose reduction index potential (GRIP). The GRIP factor is the reduction in glycemic index units per gram of fiber.(Data analysis)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Not Applicable
The effect of a novel polysaccharide blend (PGX® micro-granules) on short- term weight loss and other laboratory parameters in overweight and obese adults: an observational retrospective analysisObesityISRCTN50749194Factors Group of Nutritional Companies Inc. (Canada)29
Completed
Not Applicable
Blood Glucose Response to Highly Viscous Polysaccharide Enriched Biscuits in Healthy and Diabetic SubjectsType 2 DiabetesNCT00728143Unity Health Toronto19
Terminated
Not Applicable
Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's DiseaseCrohn's DiseaseNCT02193750University of British Columbia24
Completed
Phase 3
Effects of Saccharomyces Boulardii capsules in pediatric Inflammatory bowel diseaseIRCT20120415009475N5Shahid Beheshti University of Medical Sciences60
Unknown
Not Applicable
Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn DiseaseCrohn DiseaseUlcerative ColitisNCT03941418University Clinic Dr Dragisa Misovic-Dedinje150